Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?

Abstract

Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations suggest that only 25% of individuals with suspected HCV infection have been diagnosed, and only 4% received treatment.2 Recent availability in this region of directacting antivirals (DAAs), which are safer and more effective than the interferon-based therapies, may influence treatment paradigms at country levels.